Papers
2
Total Citations
9
H-Index
1
About
Dr. Peter Hanna is a leading researcher in urologic oncology, with a focused expertise in optimizing surgical outcomes for bladder cancer patients. His primary research centers on the implementation of Enhanced Recovery After Surgery (ERAS) protocols, particularly in the context of radical cystectomy for muscle-invasive bladder cancer. Dr. Hanna’s most impactful contribution is his seminal 2021 study, which demonstrated that the addition of alvimopan to ERAS protocols significantly reduces postoperative ileus and shortens hospital stays. This work, with 8 citations, provides critical evidence for a combined pharmacological and perioperative care strategy. His earlier 2020 study further solidified alvimopan’s role as an essential component of ERAS, showing that its use is associated with decreased length of stay and improved recovery metrics. By systematically evaluating these interventions in large patient cohorts, Dr. Hanna has provided actionable data that directly influences clinical guidelines. His research bridges the gap between surgical technique and patient-centered recovery, offering a blueprint for reducing morbidity and healthcare costs in high-risk urologic surgeries.
Research Focus
Key Achievements
Top Papers
- 1
- 2